Abstract: The continuous liquid separation is a continuous liquid separating apparatus that separates a first liquid and a second liquid that is immiscible to the first liquid and has a higher specific gravity than the first liquid, and includes: a liquid separating tank configured to contain a liquid, and be supplied with a liquid mixture of the first liquid and the second liquid, and including a first discharge portion on a lower side thereof and a second discharge portion disposed at a position higher than the first discharge portion, a valve configured to open/close the first discharge portion, a first sensor configured to detect a first water level of the liquid mixture contained in the liquid separating tank, the first water level being lower than the second discharge portion, and a second sensor configured to detect a second water level of the liquid mixture contained in the liquid separating tank.

Abstract: An object of the present invention is to provide a novel solid phase peptide synthesis method for synthesizing a large amount of a peptide. Another object of the present invention is to provide a novel solid phase peptide synthesis method for synthesizing a high-purity long-chain peptide. Still another object of the present invention is to provide a novel solid phase peptide synthesis method causing fewer side reactions. The present invention relates to a method for producing a peptide, and the method comprises solid-phase synthesis of a peptide under stirring with a centrifugal stirrer having no impeller.

Abstract: Objects of the present invention are to provide an industrially applicable method for producing an optically active ?-amino acid in high yield and in a highly enantioselective manner, to provide a simple production method of an optically active ?,?-disubstituted ?-amino acid, and to provide an intermediate useful for the above production methods of an optically active ?-amino acid and an optically active ?,?-disubstituted ?-amino acid. The present invention provides a production method of an optically active ?-amino acid or a salt thereof, the production method comprising introducing a substituent into the ? carbon in the ?-amino acid moiety of a metal complex represented by the following Formula (1): by an alkylation reaction, an aldol reaction, the Michael reaction, or the Mannich reaction, and releasing an optically pure ?-amino acid enantiomer or a salt thereof by acid decomposition of the metal complex.

Abstract: An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method.

Abstract: An object of the present invention is to provide a method for producing an optically active amino acid in high yield and in a highly enantioselective manner, which method has fewer restrictions on the material that can be used as the substrate, and to provide, among others, a compound useful as a chiral auxiliary for the method.

Abstract: A method is provided for producing optically active alcohols from ketones by reducing a ketone in the presence of an iridium(III) complex having a chiral prolinamide compound as a ligand.

Abstract: Provided are a novel chiral iridium(III) complex; and a method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines from 2-substituted-quinolines with the use of the chiral iridium(III) complex through a more economical and easy production process.

Abstract: Provided are a novel chiral iridium(III) complex; and a method for producing optically active 2-substituted-1,2,3,4-tetrahydroquinolines from 2-substituted-quinolines with the use of the chiral iridium(III) complex through a more economical and easy production process.

Abstract: The present invention provides a process for producing 2?,3?-didehydro-3?-deoxy-4?-ethynylthymidine, which is useful as a medicine, in an efficient and industrially advantageous manner, and more specifically, provides a process for producing 2?,3?-didehydro-3?-deoxy-4?-ethynylthymidine as shown below. (wherein R1 and R2 independently represent a protective group for a hydroxy group, or R1 and R2 together form a protective group for two hydroxy groups, R3 and R4 independently represent a protective group for a hydroxy group, R5 represents a protective group for a hydroxy group, R6 represents a protective group for a hydroxy group, X represents a leaving group, and Y represents a halogen atom.

Abstract: The present invention provides a method for producing chiral amines, comprising asymmetric transfer hydrogenation of imine compounds in the presence of a hydrogen donor compound and an iridium(III) complex having a chiral prolinamide compound as a ligand. The present invention is useful for production of chiral amines in an efficient manner in terms of their optical and chemical yields.

Abstract: A compound represented by formula (1), a tautomer thereof, or a salt of the compound or tautomer, which is useful as a bactericide/disinfectant. In the formula, R1 represents a hydrogen atom, an optionally substituted alkyl group or the like, R2 represents a hydrogen atom or an optionally substituted alkyl group, or alternatively R1 and R2 may combine together with an adjacent nitrogen atom to form an optionally substituted nitrogen-containing heterocyclic group; R4 represents a hydrogen atom or an optionally substituted alkyl group; R3 represents an optionally substituted alkyl group; and R5 and R6 each represents a hydrogen atom or a methyl group, excluding a compound wherein both R2 and R4 represent a hydrogen atom and a compound wherein both R1 and R4 represent a hydrogen atom are excluded.

Abstract: The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.

Abstract: A new use of a zinc tranexamate compound in the treatment of diabetes is disclosed. Oral administration of the compound adequately slows down absorption of glucose from digestive tracts by inhibiting &agr;-glucosidase in vivo. The zinc tranexamate compound is also effective in the treatment of insulin-resistant type II diabetes.

Abstract: An agent for the prevention and treatment of inflammatory bowel disease (IBD) containing at least one of zinc L-carnosine salts and complexes as an active ingredient. A use of the zinc L-carnosine salts or complexes and a therapeutic method of IBD by using the same are also disclosed.

Abstract: There are provided quaternary ammonium compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2, each independently represents a hydrogen atom, a C.sub.1 to C.sub.8 lower alkyl or alkenyl group, or C.sub.3 to C.sub.8 lower cycloalkyl, cycloalkenyl, aralkyl or aryl group; or R.sub.1 and R.sub.2 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 3- to 8- membered heterocyclic ring group: R.sub.3, R.sub.4 and R.sub.5, each independently represents a C.sub.1 to C.sub.8 lower alkyl or alkenyl group, C.sub.3 to C.sub.8 lower cycloalkyl, cycloalkenyl, aralkyl or aryl group; or either two of R.sub.3, R.sub.4 and R.sub.5 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 3- or 8-membered heterocyclic ring group, with the remaining being the same as defined in the above; or R.sub.3, R.sub.4 and R.sub.

Abstract: A novel crystalline L-carnosine zinc complex is produced by reacting L-carnosine, a zinc salt and an alkali metal compound in an anhydrous or hydrous polar organic solvent.The crystalline L-carnosine zinc complex substantially corresponds to the formula C.sub.9 H.sub.12 N.sub.4 O.sub.3 Zn and has physical properties clearly different from the known amorphous L-carnosine zinc complex.As compared with the amorphous complex, the crystalline complex is very low in impurity, stable to heat and moisture, and easy to filtrate, and has higher anti-ulcer activity.

Abstract: Novel pheophorbide derivatives of the general formula: ##STR1## [wherein Z is O or NH; n is an integer of 1 to 6; Y is NR'R" or ##STR2## wherein R', R" and R'" are the same or different or each represents a C.sub.1 to C.sub.4 lower alkyl group; X.sup.- is a halogen or organic acid ion); R.sub.1 is an ethenyl group; C.sub.1 to C.sub.4 lower alkyl group or ##STR3## (wherein m is an integer of 0 to 6; R.sub.6 is H or a C.sub.1 to C.sub.4 lower alkyl group); R.sub.2 is CH.sub.3, CHO or CH.sub.2 OH; either of R.sub.3 and R.sub.4 is H, with the other being OH, or both of them combine to represent .dbd.O; R.sub.5 is H or CO.sub.2 CH.sub.3) are provided.When administered to a cancer-carrying animal, the derivatives accumulate specifically in cancer tissues and emit characteristic fluorescent spectrum under irradiation of light, which enables one to detect the cancer tissues.

Abstract: There are provided acetamide compounds represented by the following formula; ##STR1## wherein R.sub.1 and R.sub.2 each independently represents a hydrogen atom, a C.sub.1 to C.sub.6 straight- or branched-chain alkyl or alkenyl group, a C.sub.3 to C.sub.6 cycloalkyl or cycloalkenyl group, or a C.sub.6 to C.sub.10 aromatic group; or R.sub.1 and R.sub.2 combine with each other in combination with the adjacent N and carbon atoms or further with at least one of nitrogen, oxygen and sulfur atoms to represent a 5- to 6-membered heterocyclic ring group; R.sub.3 represents hydrogen atom, a C.sub.1 to C.sub.6 straight- or branched-chain alkyl or alkenyl group, a C.sub.3 to C.sub.6 cycloalkyl or cycloalkenyl group, a halogen atom, a C.sub.1 to C.sub.6 straight- or branched-chain alkyloxy group, or a C.sub.3 to C.sub.6 cycloalkyloxy or cycloalkenyloxy group; and n is an integer of 1 to 4, and their pharmaceutically acceptable salts.

Abstract: A new preventive and therapeutic agent given by oral administration containing carnosine zinc salt as the effective component and, effective against alcoholic liver disorder, viral hepatitis or liver disorders caused by drugs, toxicants, radiation, etc.

Abstract: N.sup..epsilon. -Trifluoroacetyl-L-lysyl-L-proline.D-10-camphorsulfonic acid salt is produced in very high purity by reacting N.sup..epsilon. -trifluoroacetyl-L-lysyl-L-proline with D-10-camphorsulfonic acid in a suitable solvent, followed by crystallization from the reaction mixture.The salt is extremely stable at a temperature of working ambience as compared with other salts of N.sup..epsilon. -trifluoroacetyl-L-lysyl-L-proline including known dicyclohexylamine salt of the same.